A Single-blind, Randomized, Placebo-controlled, Phase 1, Single Ascending-dose and Repeat-dose, Safety and Tolerability Study of Intravenous AVB-S6-500 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2019
Price : $35 *
At a glance
- Drugs Aravive S6 (Primary)
- Indications Acute myeloid leukaemia; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Aravive Biologics
- 16 Nov 2018 Results presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- 13 Nov 2018 Results presented in an Aravive Media Release.
- 13 Nov 2018 According to an Aravive Biologics media release, detailed data were presented at at the Molecular Targets and Cancer Therapeutics 2018 EORTC-NCI-AACR Symposium.